drugset / Trial / NCT07830758
Resmetirom in Patients With MASH and HFpEF
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.
Timeline
- Start
- 2026-09
- Primary completion
- 2027-11
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resmetirom | Small molecule | 80 mg | Oral |
| Subject | Resmetirom | Small molecule | 100 mg | Oral |